Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up
Nephrology Dialysis Transplantation · 04.05.2023 · 38 (5) · 1183-1191
DOI: 10.1093/ndt/gfac225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 29.07.2022. Verfasst von Yngvar Lunde Haaskjold und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Kidney Failure, Chronic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Recently, two immunoglobulin A (IgA) nephropathy-prediction tools were developed that combine clinical and histopathologic parameters. The International IgAN Prediction Tool predicts the risk for 50% declines in the estimated glomerular filtration rate or end-stage kidney disease up to 80 months after diagnosis. The IgA Nephropathy Clinical Decision Support System uses artificial neural networks to estimate the risk for end-stage kidney disease. We aimed to externally validate both prediction tools using a Norwegian cohort with a long-term follow-up.
Methods
We included 306 patients with biopsy-proven primary IgA nephropathy in this study. Histopathologic samples were retrieved from the Norwegian Kidney Biopsy Registry and reclassified according to the Oxford Classification. We used discrimination and calibration as principles for externally validating the prognostic models.
Results
The median patient follow-up was 17.1 years. A cumulative, dynamic, time-dependent receiver operating characteristic analysis showed area under the curve values ranging from 0.90 at 5 years to 0.83 at 20 years for the International IgAN Prediction Tool, while time-naive analysis showed an area under the curve value at 0.83 for the IgA Nephropathy Clinical Decision Support System. The International IgAN Prediction Tool was well calibrated, while the IgA Nephropathy Clinical Decision Support System tends to underestimate risk for patients at higher risk and overestimates risk in the lower risk categories.
Conclusions
We have externally validated two prediction tools for IgA nephropathy. The International IgAN Prediction Tool performed well, while the IgA Nephropathy Clinical Decision Support System has some limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Haukeland University Hospital, Bergen, Norway.
- Renal Research Group, Department of Clinical Medicine, University of Bergen, Norway.
- Department of Radiology, Haukeland University Hospital, Bergen, Norway.
- Emergency Care Clinic, Haukeland University Hospital, Bergen, Norway.
- Department of Pathology, Haukeland University Hospital, Bergen, Norway.
ORCID-Profile: Yngvar Lunde Haaskjold, Rune Bjørneklett
Zitieren
APA
Haaskjold, Y. L., Lura, N. G., Bjørneklett, R., Bostad, L., Bostad, L. S., & Knoop, T. (2023). Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up. Nephrology Dialysis Transplantation, 38(5), 1183-1191. https://doi.org/10.1093/ndt/gfac225
Vancouver
Haaskjold YL, Lura NG, Bjørneklett R, Bostad L, Bostad LS, Knoop T. Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up. Nephrology Dialysis Transplantation. 2023;38(5):1183-1191. doi:10.1093/ndt/gfac225
BibTeX
@article{Haaskjold2023,
author = {Haaskjold, Yngvar Lunde and Lura, Njål Gjærde and Bjørneklett, Rune and Bostad, Leif and Bostad, Lars Sigurd and Knoop, Thomas},
title = {Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
volume = {38},
number = {5},
pages = {1183--1191},
doi = {10.1093/ndt/gfac225}
}
EUVIMED